Two studies published back to back in Nature have looked at the accumulation of mutations in blood-forming stem cells with age, gaining new insights into how the overall landscape of such cells changes across the lifespan.
Four scientists have shared the 2022 Kavli Prize in neuroscience, "for pioneering the discovery of genes underlying a range of serious brain disorders," together and separately.
By analyzing single-cell responses to ketamine administration, a multinational team of researchers has identified a potassium channel that contributes to the long duration of ketamine administration.
In two separate studies, researchers have identified how peripheral nerve injury can lead to increased pain sensitivity. The studies were published on May 25, 2022, in Nature and May 26, 2022, in Science, respectively. The mechanisms they identify could lead to new therapeutic approaches to chronic pain and/or pain hypersensitivity.
A new study is shedding further light on the link between aging and neurodegenerative disease, after researchers found that protein turnover occurs about 20% slower in the brains of older mice compared with younger mice, affecting distinct pathways linked to these diseases.
New research points a finger at a previously unknown long noncoding RNA (lncRNA) as playing a critical role in activating nuclear factor kappa B (NF-kappaB) inflammatory responses and driving the progression of osteoarthritis of the knee.
Jack Taunton and colleagues from the University of California, San Francisco have developed salicylaldehyde-based chemical probes that reversibly and covalently modify the catalytic lysine of protein kinases, with sustained occupancy in cells and animals.
Variable expression of an enzyme in the initial tumor has been identified as an early step in the process of migration and growth of cells to form remote metastases in breast cancer.
A German-Danish team of researchers has developed a new imaging technology that is able to quantify the number of expressed proteins in a given cell, map tissue and cell-type specific proteomes, and identify drug targets.
A multicenter Japanese study led by researchers at Tokyo University of Science has confirmed that the epithelial phospholipid, phosphatidylinositol bisphosphate, could partially halt cancer progression, making it an attractive new target molecule for novel anticancer treatments.
RSS
